Anna Schwendeman

Dr. Anna Schwendeman’s laboratory is working on optimization of synthetic HDL (sHDL) compositions for treatment of atherosclerosis, lysosomal storage diseases, sepsis as well as vaccine and drug delivery purposes.

Research Areas:

Cardiovascular Research, Biomedical Innovation

When Dr. Schwendeman moved to the United States in 1994, she changed her field of study to Pharmaceutical Chemistry and initially worked on stabilization and controlled release of anticancer drugs from injectable poly(lactic-co-glycolic acid) (PLGA) delivery systems. After receiving her Ph.D. in 2000, she joined a small biotech company Esperion Therapeutics and moved into cardiovascular research. During this time in biotech, she oversaw HDL nanoparticle formulation, cGMP recombinant protein manufacturing, analytical release and stability studies, pharmacology, and toxicology evaluation of five synthetic HDL products: ETC-216, CER-001, ETC-642, CER-522 and ETC-588. For some of these products, she oversaw the entire translation process from bench discovery to the end of Phase II clinical trials. Her group was responsible for regulatory submissions for seven FDA INDs. In 2012, she received an appointment at the University of Michigan as an Assistant Professor in the Department of Pharmaceutical Sciences. Her laboratory is working on optimization of synthetic HDL (sHDL) compositions for treatment of atherosclerosis, lysosomal storage diseases, sepsis as well as vaccine and drug delivery purposes.

she/her/hers

• Keyserling CH, Hunt TL, Klepp HM, Barbaras R, Schwendeman A, Lalwani N, Dasseux J. A First-in-human, randomized, double-blind, ascending single-dose, placebo-controlled, two-period crossover study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous CER-001 in Healthy Dyslipidemic Volunteers. AHA; 2011 November; Chicago, IL, USA.
• 1. Merlet N, Busseuil D, Mihalache-Avram T, Mecteau M, Shi Y, Nachar W, Brand G, Brodeur MR, Charpentier D, Rhainds D, Sy G, Schwendeman A, Lalwani N, Dasseux JL, Rhéaume E, Tardif JC. HDL mimetic peptide CER-522 treatment regresses left ventricular diastolic dysfunction in cholesterol-fed rabbits. Int J Cardiol. 2016 Jul 15;215:364-71. PubMed PMID: 27128563.
• 1. Morin EE, Guo L, Schwendeman* A, Li* XA, HDL in sepsis – risk factor and therapeutic approach. Front Pharmacol. 2015;6:244. PubMed PMID: 26557091; PubMed Central PMCID: PMC4616240.
• Schwendeman* A, Sviridov DO, Yuan W, Guo Y, Morin EE, Yuan Y, Stonik J, Freeman L, Ossoli A, Thacker S, Killion S, Pryor M, Chen YE, Turner S, Remaley AT. The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties. J Lipid Res. 2015 Sep;56(9):1727-37. PubMed PMID: 26117661; PubMed Central PMCID: PMC4548777.
• Kuai R, Ochyl LJ, Bahjat KS, Schwendeman* A, Moon* JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017 Apr;16(4):489-496. PubMed PMID: 28024156; PubMed Central PMCID: PMC5374005. *Co-corresponding authors.
• 1. Yuan Y, Wen J, Tang J, Kan Q, Ackermann R, Olsen K, Schwendeman* A. Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin. Int J Nanomedicine. 2016;11:6229-6238. PubMed PMID: 27920529; PubMed Central PMCID: PMC5125756.
• 1. Kuai R, Li D, Chen YE, Moon* JJ, Schwendeman* A. High-density lipoproteins: nature’s multifunctional nanoparticles. ACS Nano. 2016 Mar 22;10(3):3015-41. PubMed PMID: 26889958; PubMed Central PMCID: PMC4918468.
• Complete List of Published Work in Her Bibliography

• 2019 – Associate Editor, European Journal Pharmaceutics and Biopharmaceutics
• 2018 – now Associate Professor, College of Pharmacy, The University of Michigan, Ann Arbor, MI
• 2017- Grant Reviewer, AAAS Research Competitiveness Program
• 2017 -Consultant, Capstone Development Services, Rosemont, IL
• 2016 -Associate Editor, Nanomedicine: Nanotechnology, Biology and Medicine

• 2014 Winner of “Biomedical Innovation Shark Tank” hosted by Michigan Economic Development Corp.
• 2013 Scientist Development Grant Award, American Heart Association
• 2013 Editorial Advisory Board, J. Pharm. Sci.
• 1999 Presidential Fellowship, The Ohio State University